Calls
1
u/Nix_100
Reddit r/biotech_stocks
Win Rate
100.0%
return
+0.7%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Sep 14
$37.38
+0.7%
Immunovant's Phase 2 trial for IMVT-1402 in Cutaneous Lupus is expected to read out positively, with the author assigning a 65-70% probability of success based on FcRn inhibition reducing pathogenic IgG autoantibodies and validation from J&J's Nipocalimab in SLE. The catalyst is the Phase 2 topline readout (estimated primary completion October 2026), with a target price of $45-$50 from the current ~$37, implying ~35% upside. The main risk is that early proof-of-concept data was from a small, open-label study without placebo control, and SLE is different from CLE.
Construction & Infrastructure
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/Nix_100 has 1 trade ideas tracked on Buzzberg across 1 tickers since September 2026. Most covered: IMVT.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
